Business
Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution
Collaboration Eases Patient Access to Therapy LAKE FOREST, Ill., March 31, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT) and
About this update from Assertio Holdings, Inc.
[{"type":"text","content":"Collaboration Eases Patient Access to Therapy\nLAKE FOREST, Ill., March 31, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT) and BlinkRx, the leading patient access solution, today announced a collaboration to support healthcare professionals and their patients undergoing treatment with Otrexup. This prescription medication is a drug device combination single-dose, once-weekly, auto-injector containing methotrexate for subcutaneous injections. BlinkRx's program helps reduce barriers patients may encounter in having access to their medications. Patients benefit from transparent low prices, free home delivery, and world-class support. BlinkRx is incredibly easy to use for both patients and providers. When providers send a prescription to BlinkRx, their patient immediately receives a text with their lowest available price, including any eligible copay support. Patients can check out securely online or by phone. Otrexup will be delivered with no shipping fees. “We are thrilled to partner with a leading digital pharmacy provider in BlinkRx that offers a compelling, convenient option and which aligns to our strategy of leveraging our digital platform and virtual engagement to better serve our patients,” said Dan Peisert, President and Chief Executive Officer of Assertio. “This builds upon our existing pharmacy hub capabilities with a new direct to patient model for those who prefer a convenient digital option.” About Otrexup Otrexup is a single-dose auto-injector containing a prescription medicine, methotrexate. Methotrexate is used to: Treat certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal anti-inflammatory drugs (NSAIDS) have been used and did not work well.Control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well. Otrexup should not be used for the treatment of cancer. Otrexup should not be used for the treatment of children with psoriasis. Otrexup can cause serious side effects that can lead to death, including organ system toxicity People who use methotrexate for the treatment of cancer, psoriasis, or rheumatoid arthritis, have an increased risk of death from organ toxicity. Typ...